

QIPS 2025: Adult program

Statin Therapy for Patients with Diabetes

 Tertiary Focus | Statin Therapy



Measure Requirements

Continuously enrolled **Commercial** members ages 40 through 75 as of December 31, 2025, identified with diabetes who do not have clinical ASCVD.

Member Requirements

The percentage of Commercial members ages 40 through 75 during the measurement year (2025) with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria. Two rates are reported:

- 1. Received Statin Therapy.** Members who were dispensed at least one statin medication of any intensity during the measurement year (2025).
- 2. Statin Adherence 80%.** Members who remained on a statin medication of any intensity for at least 80% of the treatment period.

QPM Targets

Band 1	69% – 100%
Band 2	67% – 68.99%
Band 3	64% – 66.99%
Band 4	61% – 63.99%
Band 5	<61%

See payment details in section 5 of the QIPS guide.

Independence Blue Cross offers products through its subsidiaries Independence Assurance Company, Independence Hospital Indemnity Plan, Keystone Health Plan East, and QCC Insurance Company — independent licensees of the Blue Cross and Blue Shield Association.



Options to close Care Gaps

- **Option 1:** Claim/encounter submission with appropriate coding of pharmaceuticals from a pharmacy.

Description	Prescription		
Low-intensity statin therapy	Simvastatin 5 – 10 mg	Ezetimibe-simvastatin 10 mg	Pravastatin 10 – 20 mg
	Lovastatin 20 mg	Fluvastatin 20 – 40 mg	
Moderate-intensity statin therapy	Atorvastatin 10 – 20 mg	Amlodipine-atorvastatin 10 – 20 mg	Rosuvastatin 5 – 10 mg
	Simvastatin 20 – 40 mg	Ezetimibe-simvastatin 20 – 40 mg	Pravastatin 40 – 80 mg
	Lovastatin 40 mg	Fluvastatin 40 mg bid	Pitavastatin 2 – 4mg
High-intensity statin therapy	Atorvastatin 40 – 80 mg	Amlodipine-atorvastatin 40 – 80 mg	Rosuvastatin 20 – 40 mg
	Simvastatin 80 mg	Ezetimibe-simvastatin 80 mg	

- **Option 2:** Claim/encounter submission with appropriate exclusion coding for members who meet any of the following criteria on or prior to December 31 of the measurement year.

Exclusion codes				
Muscular Pain & Disease	M62.82 – Rhabdomyolysis		G72.9 – Myopathy, Unspecified	
	M60.9 – Myositis, Unspecified		M79.11 – Myalgia	
	G72.0 – Drug-Induced Myopathy		M60.80 – Other Myositis, Unspecified site	
Diabetes mellitus due to underlying conditions	E08.311	E08.3319	E08.3519	E08.3559
	E08.319	E08.3399	E08.3529	E08.3599
	E08.3219	E08.3419	E08.3539	E08.37X9
	E08.3299	E08.3499	E08.3549	E08.40
Drug or chemical induced Diabetes mellitus	E09.311	E09.319	E09.3219	E09.3299
	E09.3319	E09.3399	E09.3419	E09.3499
	E09.3519	E09.3529	E09.3539	E09.3549
	E09.3559	E09.3599	E09.37X9	E09.40

Exclusion codes				
Dialysis Procedure	90935	90937	90945	90947
	90997	90999	99512	
	G0257	S939		
Gestational Diabetes	O24.410	O24.414	O24.415	O24.419
	O24.420	O24.424	O24.425	O24.429
	O24.430	O24.434	O24.435	O24.439
	O24.911	O24.912	O24.913	O24.919
	O24.92	O24.92		
In Vitro Fertilization	S4015	S4016	S4018	S4020
	S4021			
Myopathy	G72.0	M60.80		
Polycystic Ovarian Syndrome	E28.2			
End Stage Renal Disease	N18.5	N18.6	Z99.2	
Cirrhosis	K70.30	K70.31	K71.7	K74.3
	K74.4	K74.5	K74.60	K74.69
	P78.81			
Pregnancy	O80	Z36.89	Z36.82	Z36.3